PE20211479A1 - Composicion farmaceutica y metodo de fabricacion - Google Patents
Composicion farmaceutica y metodo de fabricacionInfo
- Publication number
- PE20211479A1 PE20211479A1 PE2020001435A PE2020001435A PE20211479A1 PE 20211479 A1 PE20211479 A1 PE 20211479A1 PE 2020001435 A PE2020001435 A PE 2020001435A PE 2020001435 A PE2020001435 A PE 2020001435A PE 20211479 A1 PE20211479 A1 PE 20211479A1
- Authority
- PE
- Peru
- Prior art keywords
- range
- pharmaceutical composition
- metaarsenite
- enteric
- approximately
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente solicitud se refiere a una composicion farmaceutica adecuada para la administracion oral que comprende: a) un nucleo solido compuesto por metaarsenito de sodio o metaarsenito de potasio y excipientes farmaceuticos tales como: i) un material de relleno o diluyente en un rango de aproximadamente 5 a 95% p/p, ii) un desintegrante en un rango de 10 y 90% p/p, iii) un deslizante en un rango de aproximadamente 0,1 a 5% p/p, iv) un lubricante en un rango de aproximadamente 0,1 a 5% p/p, y v) opcionalmente, un aglutinante en un rango de 0 a aproximadamente 30% p/p; y b) un cubierta enterica que comprende un polimero enterico; donde los excipientes de uso farmaceutico aceptable estan seleccionados de tal forma que la oxidacion de metaarsenito a metaarseniato esta minimizada, donde el porcentaje en peso de la cubierta enterica es de 6% p/p a 20% p/p con respecto al peso total de la composicion farmaceutica, y donde el grosor de la cubierta es de 6,5% a 15% del grosor de la composicion farmaceutica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018900954A AU2018900954A0 (en) | 2018-03-22 | Pharmaceutical composition and method of manufacture | |
| PCT/AU2019/050249 WO2019178643A1 (en) | 2018-03-22 | 2019-03-21 | Pharmaceutical composition comprising meta arsenite and method of manufacture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211479A1 true PE20211479A1 (es) | 2021-08-05 |
Family
ID=67988234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001435A PE20211479A1 (es) | 2018-03-22 | 2019-03-21 | Composicion farmaceutica y metodo de fabricacion |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20210000746A1 (es) |
| EP (1) | EP3768247A4 (es) |
| JP (1) | JP7419333B2 (es) |
| KR (1) | KR20210016513A (es) |
| CN (1) | CN112135608A (es) |
| AR (1) | AR114596A1 (es) |
| AU (1) | AU2019239671A1 (es) |
| BR (1) | BR112020019425A2 (es) |
| CA (1) | CA3094115A1 (es) |
| CL (1) | CL2020002407A1 (es) |
| CO (1) | CO2020012963A2 (es) |
| EA (1) | EA202092186A1 (es) |
| IL (1) | IL277456A (es) |
| JO (1) | JOP20200238A1 (es) |
| MA (1) | MA52088A (es) |
| MX (1) | MX2020009756A (es) |
| PE (1) | PE20211479A1 (es) |
| PH (1) | PH12020551518A1 (es) |
| SG (1) | SG11202009174WA (es) |
| WO (1) | WO2019178643A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230123135A1 (en) * | 2020-02-16 | 2023-04-20 | Komipharm International Australia Pty Ltd | Method of treatment using meta-arsenite |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
| US5318973A (en) * | 1993-06-07 | 1994-06-07 | Vyzkumny Ustav Pro Farmacii A Biochemii | Neuroprotective composition for preventing or treating of central nervous system impairment |
| JP4036936B2 (ja) * | 1997-10-22 | 2008-01-23 | 古河機械金属株式会社 | 排酸の処理法 |
| US6262086B1 (en) * | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
| KR20020083678A (ko) * | 2001-04-28 | 2002-11-04 | 주식회사 한국미생물연구소 | 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물 |
| CA2471715A1 (en) * | 2001-12-28 | 2003-07-17 | Teva Pharmaceutical Industries Ltd. | A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof |
| US20090061022A1 (en) * | 2004-10-08 | 2009-03-05 | Sang Bong Lee | Pharmaceutical composition comprising arsenite for the treatment of malignancy |
| WO2006104292A1 (en) * | 2005-03-31 | 2006-10-05 | Komipharm International Co., Ltd. | Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts |
| EP1721615A1 (en) * | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| US8945505B2 (en) * | 2007-02-02 | 2015-02-03 | Panaphix, Inc. | Use of arsenic compounds for treatment of pain and inflammation |
| KR20090058423A (ko) * | 2007-12-04 | 2009-06-09 | 심형섭 | 소디움 메타아르세나이트를 함유하는 ｃ형 바이러스성 간염치료용 조성물 |
| US20090246291A1 (en) * | 2008-03-27 | 2009-10-01 | Angelika Burger | Method and compositions for treatment of cancer |
| US20120045520A1 (en) * | 2008-08-21 | 2012-02-23 | Sang Bong Lee | Pharmaceutical composition comprising arsenite for the treatment of malignancy |
| MX2012002922A (es) * | 2009-09-18 | 2012-09-07 | Kominox Inc | Metodos para tratar tumores del cerebro. |
-
2019
- 2019-03-21 WO PCT/AU2019/050249 patent/WO2019178643A1/en unknown
- 2019-03-21 EA EA202092186A patent/EA202092186A1/ru unknown
- 2019-03-21 CN CN201980028836.3A patent/CN112135608A/zh active Pending
- 2019-03-21 CA CA3094115A patent/CA3094115A1/en active Pending
- 2019-03-21 SG SG11202009174WA patent/SG11202009174WA/en unknown
- 2019-03-21 JP JP2021500320A patent/JP7419333B2/ja active Active
- 2019-03-21 KR KR1020207030401A patent/KR20210016513A/ko active Search and Examination
- 2019-03-21 PE PE2020001435A patent/PE20211479A1/es unknown
- 2019-03-21 AU AU2019239671A patent/AU2019239671A1/en active Pending
- 2019-03-21 BR BR112020019425-5A patent/BR112020019425A2/pt unknown
- 2019-03-21 MA MA052088A patent/MA52088A/fr unknown
- 2019-03-21 MX MX2020009756A patent/MX2020009756A/es unknown
- 2019-03-21 JO JOP/2020/0238A patent/JOP20200238A1/ar unknown
- 2019-03-21 EP EP19770346.5A patent/EP3768247A4/en active Pending
- 2019-03-21 US US16/982,399 patent/US20210000746A1/en active Pending
- 2019-03-21 AR ARP190100727A patent/AR114596A1/es unknown
-
2020
- 2020-09-17 CL CL2020002407A patent/CL2020002407A1/es unknown
- 2020-09-21 PH PH12020551518A patent/PH12020551518A1/en unknown
- 2020-09-21 IL IL277456A patent/IL277456A/en unknown
- 2020-10-16 CO CONC2020/0012963A patent/CO2020012963A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021518434A (ja) | 2021-08-02 |
| AU2019239671A1 (en) | 2020-10-01 |
| JP7419333B2 (ja) | 2024-01-22 |
| CO2020012963A2 (es) | 2020-10-30 |
| EA202092186A1 (ru) | 2020-12-16 |
| JOP20200238A1 (ar) | 2020-09-20 |
| IL277456A (en) | 2020-11-30 |
| CL2020002407A1 (es) | 2021-04-09 |
| CN112135608A (zh) | 2020-12-25 |
| SG11202009174WA (en) | 2020-10-29 |
| EP3768247A1 (en) | 2021-01-27 |
| CA3094115A1 (en) | 2019-09-26 |
| PH12020551518A1 (en) | 2021-07-12 |
| MX2020009756A (es) | 2021-01-29 |
| WO2019178643A1 (en) | 2019-09-26 |
| KR20210016513A (ko) | 2021-02-16 |
| AR114596A1 (es) | 2020-09-23 |
| BR112020019425A2 (pt) | 2020-12-29 |
| US20210000746A1 (en) | 2021-01-07 |
| EP3768247A4 (en) | 2021-12-29 |
| MA52088A (fr) | 2021-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001625A1 (es) | Derivados de pirazolilo útiles como agentes anti-cancerígenos | |
| CL2019002810A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos. | |
| PE20091971A1 (es) | Formulaciones orales de analogos de citidina y metodos de uso de los mismos | |
| CL2017000379A1 (es) | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7) | |
| CL2021001430A1 (es) | Composiciones de glp-1 y sus usos. (divisional de solicitud 202000422) | |
| UY37098A (es) | Moduladores de ror-gamma | |
| CO2018005842A2 (es) | Composición farmacéutica que comprende un potente inhibidor de urat 1 | |
| CR20140185A (es) | Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio | |
| GT200900280A (es) | Derivados de 2 piridin carboxamida como moduladores de los canales de sodio | |
| UY31261A1 (es) | Imidazopiridinonas, composiciones que las contienen, procedimientos para su preparacion, intermedios utilizados en tales procedimientos y aplicaciones. | |
| AR077546A1 (es) | Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos | |
| CU20170159A7 (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
| BR112013020404A2 (pt) | formulações de l-mentol multiparticulado e métodos relacionados | |
| PE20161385A1 (es) | Formulacion inmunosupresora | |
| MX2023006856A (es) | Composiciones de polvo seco con estearato de magnesio. | |
| CL2017001483A1 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
| EA202092829A1 (ru) | Композиции тофацитиниба с контролируемым высвобождением | |
| DOP2019000228A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| CL2015002466A1 (es) | Formulaciones de compuestos orgánicos | |
| PE20211479A1 (es) | Composicion farmaceutica y metodo de fabricacion | |
| PE20080313A1 (es) | Formulaciones de liberacion pulsada de fenilefrina y composiciones farmaceuticas | |
| CL2017001588A1 (es) | Ácidos piridil-cicloalquil-carboxílicos sustituidos, composiciones que los contienen y usos de los mismos | |
| BR112017028185A2 (pt) | composições farmacêuticas sólidas para tratar hcv |